Following a thorough examination of the existing information, the antiviral was confirmed to be both safe and effective.
According to the Medicines and Healthcare Products Regulatory Agency (MHRA), the antiviral Molnuvir (molnupiravir) is safe and effective in reducing the risk of hospitalization and death in persons with mild to moderate COVID-19 who are at high risk of developing severe disease.
The Commission on Human Medicines, the UK regulator, and the government’s independent expert scientific advisory body, the Commission on Human Medicines, conducted a thorough review of its safety, quality, and effectiveness, making it the first oral antiviral for the treatment of COVID-19 to be approved.
Molnuvir acts by preventing the virus from replicating. This stops it from growing, decreasing the severity of the disease by keeping viral levels low in the body.
Molnuvir (Molnupiravir) is most effective in the early stages of infection, according to clinical trial data, hence the MHRA recommends using it as soon as possible after a positive COVID-19 test and within five days of symptom onset.
Molnupiravir is approved for use in people with mild to moderate COVID-19 and at least one risk factor for severe illness. Obesity, advanced age (>60 years), diabetes mellitus, and heart disease are all risk factors.
Sriya Life Science is a pharmaceutical company, pharmaceutical bulk cargo exporter, bulk pharma supplier, and wholesaler with operations in Brazil, Cambodia, Venezuela, the Philippines, Nigeria, Seychelles, and Sudan. Molnuvir is an antiviral that can be used to treat a range of viruses.